To investigate the effect of Shenyi capsule on maintaining therapeutic treatment of advanced non small cell lung cancer (NSCLC).Methods:Total 62 patients with stage Ⅲ b~Ⅳ NSCLC in our hospital from 2012 February to 2014 June were chosen to study the effect of paclitaxel combined with cisplatin treatment without progression free first-line chemotherapy. They were randomly divided into control group(n=30) and observation group(n=32) by the random number table method. The control group received pemetrexed for the treatment and the observation group received Shenyi capsule maintenance treatment respectively. The effective rate and clinical benefit rate, immune function, improvement of life quality, adverse reaction and the prognosis of the patients after two courses’ treatment in the two groups were all compared.Results:After two courses’ treatment, the total effective rate and clinical benefit rate of the observation group were better than those of the control group（χ2=5.489、6.441，P<0.05). The improvement of life quality and the cellular immunological indexes of the observation group after the treatment were all higher than those of the control group（P<0.05). And no obvious adverse reactions were found in the two groups. By the end of the follow-up in this study, the average follow-up time was (35±6.5) m, the follow-up rate was 91.9%. There were no statistically significant differences in the survival rates of 1 or 2 year’s survival rate in the two group (P>0.05).Conclusion:Shenyi capsule, as a treatment for advanced NSCLC, can improve the short-term benefit rate, the quality of life and the immunity of NSCLC patients with good security, which is applicable for clinical promotion.